Bristol-Meyers Squibb Acquires iPierian for $725,000,000

  • Feed Type
  • Date
    4/29/2014
  • Company Name
    iPierian
  • Mailing Address
    951 Gateway Blvd South San Francisco, CA 94080 USA
  • Company Description
    iPierian is a pioneering biopharmaceutical company that is taking the cutting-edge technologies of cellular reprogramming and directed differentiation to an entirely new level to harness the power of induced pluripotent stem cells to advance the understanding of human diseases and accelerate the discovery of more effective therapeutics for patients.
  • Website
    http://www.ipierian.com
  • Transaction Type
    M&A
  • Transaction Amount
    $725,000,000
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Under the terms of the agreement, Bristol-Myers Squibb has acquired all of iPierian’s issued and outstanding shares of capital stock and all common stock equivalents in an all cash transaction for a purchase price of $175 million, with the potential for additional development and regulatory milestone payments totaling $550 million, along with future royalties on net sales.

Trending on Xconomy